The DOI matches its Crossref record.
Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Abstract
Paclitaxel is one of the best antineoplastic drugs found from nature in the past decades, which has been found effective against a wide spectrum of cancers including ovarian cancer, breast cancer, small and non small cell lung cancer, colon cancer, head and neck cancer, multiple myeloma, melanoma, and Kaposi's sarcoma. Like many other anticancer drugs, it has difficulties in clinical administration due to its poor solubility in water and most pharmaceutical reagents. In its current clinical application, an adjuvant called Cremophor EL has to be employed, which has been found to be responsible for many serious side effects. Nanoparticles of biodegradable polymers can provide an ideal solution to such an adjuvant problem and realize a controlled and targeted delivery of the drug with better efficacy and less side effects. With further development, such as particle size optimization and surface coating, nanoparticle formulation of paclitaxel can promote a new concept of chemotherapy to realize its full efficacy and to improve quality of life of the patients, which includes personalized chemotherapy, local chemotherapy, sustained chemotherapy, oral chemotherapy, chemotherapy across the blood-brain barrier, chemotherapy across the microcirculation barrier, etc. The present research proposes a novel formulation for fabrication of nanoparticles of poly(lactic-co-glycolic acid) (PLGA) by a modified solvent extraction/evaporation technique, in which natural emulsifiers, such as phospholipids, cholesterol and vitamin E TPGS are creatively applied to achieve high drug encapsulation efficiency, desired drug released kinetics, high cell uptake and high cytotoxicity. The nanoparticles composed of various recipes and manufactured under various conditions were characterized by laser light scattering (LLS) for size and size distribution, scanning electron microscopy (SEM) and atomic force microscopy (AFM) for morphological properties, X-ray photoelectron spectroscopy (XPS) and Fourier Transformation Infrared Spectroscopy (FTIR) for surface chemistry, zeta-potential for surface charge, and differential scanning calorimetry (DSC) for the thermogram properties. The drug encapsulation efficiency and the drug release kinetics under in vitro conditions were measured by high performance liquid chromatography (HPLC). It was found that these natural emulsifiers have great advantages for nanoparticle formulation of paclitaxel over the traditional macromolecular emulsifiers, such as polyvinyl alcohol (PVA). Nanoparticles of desired small size and narrow size distribution can be obtained. The drug encapsulation efficiency can be achieved as high as 100 %. The released kinetics can be made under control. The HT-29 cancer cell line experiment showed that after 24 hours of incubation, the cell mortality caused by the drug administered by such nanoparticle formulation could be more than 13 times higher than that caused by the free drug under similar conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Self-citationYin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Self-citationChallenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
The present and future of nanotechnology in human health care
Sahoo, S. K., Parveen, S., & Panda, J. J. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.11.008 · Cited by 905
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of Drug Targeting · doi:10.1080/10611860400015936 · Cited by 742
Vitamin E TPGS as a molecular biomaterial for drug delivery
Zhang, Z., Tan, S., & Feng, S.-S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.046 · Cited by 586
Self-citationLooking at the blood–brain barrier: Molecular anatomy and possible investigation approaches
Cardoso, F. L., Brites, D., & Brito, M. A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.05.003 · Cited by 569
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Nanoparticles in Biological Systems
Stark, W. J. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.200906684 · Cited by 535
Hybrid Nanoparticles for Detection and Treatment of Cancer
Sailor, M. J., & Park, J. (2012) · Advanced Materials · doi:10.1002/adma.201200653 · Cited by 487
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
Dinarvand, R., Sepehri, N., Manouchehri, Rouhani, & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s18905 · Cited by 453
Drug transport to brain with targeted nanoparticles
Olivier, J.-C. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.108 · Cited by 444
Zhang, Z., & Feng, S.-S. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.006 · Cited by 414
Self-citationThe uptake and intracellular fate of PLGA nanoparticles in epithelial cells
Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J., & Saltzman, W. M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.057 · Cited by 412
“An understanding of the dynamics of uptake and intracellular trafficking could provide insight into the mechanism by which drug-loaded NPs allow improved therapy when compared to free drug [4,23,24] and provide further information as to whether these vehicles are suitable for intracellular delivery of RNAi material [2…”
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs
Dong, Y., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.03.021 · Cited by 395
Self-citationPharmaceutical nanotechnology for oral delivery of anticancer drugs
Mei, L., Zhang, Z., Zhao, L., Huang, L., Yang, X.-L., Tang, J., & Feng, S.-S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.11.005 · Cited by 373
Self-citationPrenner, E., & Chiu, M. (2011) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.76463 · Cited by 373
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 368
Varma, M. V. S., & Panchagnula, R. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.04.003 · Cited by 361
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Shenoy, D. B., & Amiji, M. M. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.12.010 · Cited by 331
Juillerat-Jeanneret, L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.005 · Cited by 314
Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery
Lu, W., Zhang, Y., Tan, Y.-Z., Hu, K.-L., Jiang, X.-G., & Fu, S.-K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.027 · Cited by 311
Virus-based nanoparticles (VNPs): Platform technologies for diagnostic imaging☆
MANCHESTER, M., & SINGH, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.014 · Cited by 292
Prospects and applications of nanobiotechnology: a medical perspective
Fakruddin, M., Hossain, Z., & Afroz, H. (2012) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-10-31 · Cited by 284
RetractedDelivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Delivery of drugs and biomolecules using carbon nanotubes
Vashist, S. K., Zheng, D., Pastorin, G., Al-Rubeaan, K., Luong, J. H. T., & Sheu, F.-S. (2011) · Carbon · doi:10.1016/j.carbon.2011.05.049 · Cited by 277
Sun, B., Ranganathan, B., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.09.038 · Cited by 274
Self-citationEvanics, F., Diamente, P. R., van Veggel, F. C. J. M., Stanisz, G. J., & Prosser, R. S. (2006) · Chemistry of Materials · doi:10.1021/cm052299w · Cited by 274
Polymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., & Ravi Kumar, M. N. V. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-8418-y · Cited by 257
Wang, Y., Li, P., Truong-Dinh Tran, T., Zhang, J., & Kong, L. (2016) · Nanomaterials · doi:10.3390/nano6020026 · Cited by 255
Huda, M. N., Nafiujjaman, M., Deaguero, I. G., Okonkwo, J., Hill, M. L., Kim, T., & Nurunnabi, M. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00217 · Cited by 254
Nanoparticle-Based Delivery Systems for Vaccines
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 253
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., et al. (2006) · Blood · doi:10.1182/blood-2006-03-012534 · Cited by 253
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles
Pan, J., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.02.020 · Cited by 187
Self-citationYan, A., Von Dem Bussche, A., Kane, A. B., & Hurt, R. H. (2007) · Carbon · doi:10.1016/j.carbon.2007.08.035 · Cited by 95
Dong, Y., & Feng, S. (2006) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30684 · Cited by 81
Self-citationShah, U., Joshi, G., & Sawant, K. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2013.10.038 · Cited by 76
Metadata
- Authors
- Feng, S.-S., Mu, L., Win, K., & Huang, G.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-02-01
- Volume
- 11
- Issue
- 4
- Pages
- 413-424
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2131041162
- Cited by
- 311
- References
- 0
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.